Loading stock data…
TEVA
$34.45+1.19 (+3.58%)
After Hours$34.12-0.33 (-0.96%)· Last close Jun 9
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teva Pharmaceutical Industries Limited in the Healthcare sector is trading at $34.45 with a market capitalization of $38.2B. Wall Street consensus targets $41.27 (11 analysts), implying a +19.8% move over the next 12 months. The stock is currently near its 52-week high of $37.35, remaining 22.0% above its 200-day moving average. On fundamentals, Piotroski 9/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$34.45
Potential Downside
3.1%
Whystock Fair Value$33.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$41.27+19.8%
Range$33.00 – $50.00
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.01%
Volume
Today's trading volume
4.09M
Recent News
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
In June 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. announced a settlement and license agreement with Teva Pharmaceuticals resolving U.S. patent litigation over Jelmyto, granting Teva a non-exclusive license to sell a generic version from September 15, 2030, subject to FDA approval and regulatory review of the agreement. This settlement clarifies the expected timing of potential generic entry for Jelmyto, reducing legal uncertainty around one of UroGen’s key products. With the Jelmyto...
Veeva Falcon AI Rollout Tests Investor Patience After Share Price Slide
Veeva Systems (NYSE:VEEV) introduced its new Falcon agentic AI platform, detailing capabilities aimed at clinical, regulatory, safety, and quality workflows. The company outlined early adopter timelines and broadened the rollout of Vault AI agents across its Vault applications. Veeva announced new platform commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery, signaling wider enterprise use of its AI tools. Veeva Systems enters this phase of AI product rollout with...
Sector Update: Healthcare Stocks Gain Friday Afternoon
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the Stat
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.